Jennifer E. Sager

Physiologically Based Pharmacokinetic ( PBPK ) Modeling and Simulation Approaches : A Systematic Review of Published Models , Applications , and Model Verification s

N. Isoherranen, Jennifer E. Sager, Jingjing Yu, 2015 .

DMD # 76455 1 PHYSIOLOGICALLY BASED PHARMACOKINETIC ( PBPK ) MODEL OF THE CYP 2 D 6 PROBE ATOMOXETINE : EXTRAPOLATION TO SPECIAL POPULATIONS AND DRUG-DRUG INTERACTIONS

N. Isoherranen, Jennifer E. Sager, I. Ragueneau-Majlessi, 2017 .

Physiologically Based Pharmacokinetic Model of the CYP2D6 Probe Atomoxetine: Extrapolation to Special Populations and Drug-Drug Interactions

N. Isoherranen, Jennifer E. Sager, I. Ragueneau-Majlessi, 2017, Drug Metabolism and Disposition.

In vitro to in vivo extrapolation of the complex drug‐drug interaction of bupropion and its metabolites with CYP2D6; simultaneous reversible inhibition and CYP2D6 downregulation

N. Isoherranen, A. Nath, Jennifer E. Sager, 2017, Biochemical pharmacology.

Identification and Structural Characterization of Three New Metabolites of Bupropion in Humans.

W. L. Nelson, John Choiniere, N. Isoherranen, 2016, ACS medicinal chemistry letters.

Stereoselective Metabolism of Bupropion to OH-bupropion, Threohydrobupropion, Erythrohydrobupropion, and 4′-OH-bupropion in vitro

N. Isoherranen, Jennifer E. Sager, Lauren S. L. Price, 2016, Drug Metabolism and Disposition.

Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab.

P. Pang, A. Cathcart, E. Mogalian, 2021, The New England journal of medicine.